Developer docs
API playgroundTry for free, no card

Search company profiles

Regis Technologies

Full company profile

uuid0009zu4

Namestring
Regis Technologies
Legal namestring
Regis Technologies, Inc.
Websiteurl
registech.com
Company typeenum
Private
Founded yearint
1956
Descriptiontext

Regis Technologies is a US-based pharmaceutical services and specialty chemistry company founded in 1956 by Dr. Louis Glunz III and headquartered at 8210 Austin Avenue, Morton Grove, Illinois. The company operates a dual-business model: a chromatography products franchise and a Custom API CDMO services franchise, both anchored at a single cGMP-certified, FDA-inspected facility.

The chromatography business manufactures and distributes high-performance packed columns for analytical and preparative separations, including chiral HPLC and SFC columns (WHELK-O® 1, recognized as USP L102; Reflect™ polysaccharide phases; AZYP chiral phases; CrownSil™ crown ether phases), achiral SFC columns (Celeris™ family), reversed-phase HPLC columns (Evoke™ C18), and immobilized artificial membrane (IAM) columns for biomimetic drug-permeability screening. Adjacent specialty and imaging reagents include ultrapure ion pairing reagents, derivatizing reagents, and bioluminescent substrates (Coelenterazine, D-Luciferin, 4-Chloro-1-Naphthol). A free in-house chiral screening service tests customer compounds across 13 stationary phases with results typically returned within 3 business days.

The CDMO division provides contract development and manufacturing services for small-molecule active pharmaceutical ingredients from preclinical through commercial stages, including analytical development, process chemistry, cGMP scale-up, clinical trial material, commercial API, and high-potency API (HPAPI) manufacturing. Customers are primarily pharmaceutical and biotechnology companies, separation scientists, and drug discovery organizations. Go-to-market combines direct enterprise sales with an authorized distributor network covering more than 80 countries, including named US distributors Chrom Tech, Fisher Scientific, Peeke Scientific, and ColumnTek. On July 30, 2025, Regis Technologies was acquired by ESTEVE (Esteve Química), a Spain-headquartered global pharmaceutical company founded in 1929, bringing approximately 70 skilled professionals into ESTEVE's US operations and positioning Regis as the US foothold of a broader CDMO platform.

Short descriptiontext

Regis Technologies is a US-based, cGMP-certified pharmaceutical services company operating two businesses: a proprietary chromatography column and reagent product line sold in 80+ countries, and a custom small-molecule API CDMO including HPAPI manufacturing from preclinical to commercial stages. Acquired by Spain's ESTEVE in July 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMorton Grove, United States
HQ citystring
Morton Grove
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
chromatography columns, chiral separation products, pharmaceutical CDMO services, API contract manufacturing, specialty reagents
Industry2 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Chromatography Products and Pharmaceutical CDMO
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Chromatography Products
TypeOne Time License
Description

Sale of chromatography columns (chiral, achiral, reversed-phase, IAM), specialty reagents (ion pairing, derivatizing, imaging), and chiral screening services. Products sold directly and through distributors.

registech.com
2Custom API CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing services for active pharmaceutical ingredients from preclinical through commercial stages. Services include analytical development, process chemistry, cGMP manufacturing, quality assurance, and regulatory support.

registech.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Standard product pricing for chromatography columns and reagents
ModelUnit PricingBilling cadencePay-as-you-go
Notes

No minimum order required. Quantity discounts available for larger quantities or bulk shipments. Contact customer service or sales representative for quotes.

registech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Regis Technologies manufactures and sells high-performance chromatography columns (chiral HPLC/SFC, achiral SFC, reversed-phase HPLC, IAM) and specialty/imaging reagents, and provides contract development and manufacturing (CDMO) services for small-molecule active pharmaceutical ingredients from preclinical through commercial stages, including high-potency APIs (HPAPIs). The chromatography business supplies separation scientists globally through direct sales and authorized distributors in 80+ countries, while the CDMO division serves pharmaceutical and biotechnology customers from its Morton Grove, IL facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Improved throughput by greater than 3X with core-shell technology
+2 more records
Product overview1 text field

Regis Technologies operates as a dual-business company offering both chromatography products and CDMO services. The chromatography portfolio consists of specialized columns (chiral, achiral SFC, reversed-phase, IAM) and specialty/imaging reagents, with flagship products including Whelk-O® 1 chiral columns, Reflect™ Polysaccharide phases, and Celeris™ achiral SFC columns. The CDMO division provides contract manufacturing and development services for small-molecule APIs from preclinical through commercial stages, including HPAPI manufacturing. The company was acquired by ESTEVE in July 2025.

Product and service15 records
1Whelk-O® 1 Chiral Columns
CategoryChiral HPLC & SFC Columns
Description

Pirkle-type chiral stationary phase columns for separating enantiomers from compound families including amides, epoxides, esters, ureas, carbamates, ethers, aziridines, phosphonates, aldehydes, ketones, carboxylic acids, and alcohols. Recognized as USP L102 and available in R,R and S,S configurations for peak elution order inversion. Used by analytical and preparative separation scientists in pharmaceutical and chemical industries.

2Reflect™ Polysaccharide Chiral Phases
CategoryChiral HPLC & SFC Columns
Description

High-performance polysaccharide-based chiral columns available in both coated and immobilized versions, including C-Amylose A, I-Cellulose B, and I-Cellulose C phases. Provide excellent peak shape, improved resolution, and high loading capacity for preparative applications. Sold to separation scientists for analytical and preparative chiral separations.

3AZYP Chiral Phases
CategoryChiral HPLC & SFC Columns
Description

Novel chiral stationary phases featuring beta-cyclodextrin, hydroxylpropyl, HILIC, alkyl derivatized cyclofructan, derivatized maltodextrin, macrocyclic glycopeptide, quinine-based, teicoplanin aglycone, teicoplanin, and vancomycin chemistries bonded to 2.7 μm superficially porous particles. Used by separation scientists for difficult chiral separations.

4CrownSil™ Crown Ether Chiral Phases
CategoryChiral HPLC & SFC Columns
Description

Crown ether-based chiral columns for separating chiral compounds containing primary amines and amino acids and their derivatives, including amino alcohols and secondary amines. Sold to separation scientists requiring selective amine separations.

5Celeris™ Achiral SFC Columns
CategoryAchiral SFC Columns
Description

Family of achiral stationary phases for supercritical fluid chromatography, including Ethyl Pyridine (2EP, 4EP), Arginine, Amino, PEI, Silica, and Diol phases. Deliver high capacity, broad selectivity, excellent peak shapes, and reproducibility over long column lifetimes. Sold to analytical and preparative separation scientists.

6Evoke™ C18 Reversed-Phase Columns
CategoryReversed-Phase HPLC Columns
Description

High-performance, scalable reversed-phase HPLC columns for resolving complex samples in pharmaceutical, food, environmental, forensics, and clinical applications. Sold to analytical laboratories across multiple industries.

7IAM (Immobilized Artificial Membrane) Chromatography Columns
CategorySpecialty Chromatography Columns
Description

Phosphatidylcholine-based columns that mimic biological cell membrane surfaces for high-throughput prediction of drug membrane permeability, correlating with Caco-2 and intestinal tissue assays. Sold to drug discovery and lead optimization teams for ADME screening.

8Ion Pairing Reagents
CategorySpecialty Reagents
Description

Ultrapure ion pairing reagents for improving separation of charged analytes in HPLC, available for both anions and cations. Sold to analytical laboratories performing charged-analyte separations.

9Derivatizing Reagents
CategorySpecialty Reagents
Description

High-purity GC derivatization reagents including acylation, alkylation, silylation, and chiral derivatization reagents for modifying analyte functional groups to enable chromatographic separation and detection. Sold to analytical laboratories.

10Coelenterazine
CategoryImaging / Bioluminescent Reagents
Description

High-purity bioluminescent reagent for reporter gene assays, ELISA, HTS assays, BRET, and chemiluminescent detection of superoxides. Manufactured in FDA-inspected, GMP-certified facility. Sold to life sciences researchers.

11D-Luciferin
CategoryImaging / Bioluminescent Reagents
Description

High-purity bioluminescent substrate for in vivo and in vitro research including reporter gene assays, whole animal imaging, luciferase assays, and ATP assays. Sold to life sciences researchers.

124-Chloro-1-Naphthol
CategoryImaging / Biochemical Reagents
Description

Biochemical reagent with 99% purity for colorimetric detection of proteins. Sold to life sciences and analytical laboratories.

13Free Chiral Screening Service
CategoryAnalytical Service
Description

Complimentary chiral separation screening service that tests customer compounds across 13 chiral stationary phases under HPLC or SFC conditions to identify optimal columns and methods. Results typically returned within 3 business days. Offered to separation scientists evaluating column purchases.

14Custom API CDMO Services
CategoryPharmaceutical CDMO Services
Description

Contract development and manufacturing services for small-molecule active pharmaceutical ingredients from preclinical through commercial stages, including analytical development, process chemistry, cGMP manufacturing, clinical trial material, commercial API, regulatory and CMC support. Delivered from an FDA-inspected, cGMP-certified facility to pharmaceutical and biotechnology companies.

15HPAPI Manufacturing
CategoryPharmaceutical CDMO Services
Description

High-potency active pharmaceutical ingredient manufacturing capabilities within cGMP facilities for compounds requiring specialized handling and containment. Delivered to pharmaceutical and biotechnology companies as part of Regis's CDMO offerings.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-30
Description

ESTEVE CDMO acquired Regis Technologies in July 2025, enabling ESTEVE to expand its contract development and manufacturing services for small-molecule APIs into the US market. The acquisition provides ESTEVE with physical US presence and Regis's cGMP manufacturing capabilities and chromatography product portfolio.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1MilliporeSigma (Merck KGaA Life Science)
TypeBroad incumbent
Description

MilliporeSigma is the dominant broad-line chromatography and lab supplies vendor with a comprehensive chiral and reversed-phase column portfolio. Competes with Regis across all chromatography segments but as part of a much larger lab products portfolio.

TypeDirect peer
Description

Chiral Technologies, the Daicel subsidiary focused exclusively on chiral chromatography, is the most direct competitor to Regis's chiral stationary phase business. Overlaps heavily with Regis's Whelk-O® 1 and Reflect™ product lines.

TypeDirect peer
Description

Daicel, through its Chiral Technologies subsidiary, is the global market leader in polysaccharide-based chiral stationary phases (Chiralcel, Chiralpak). Direct competitor to Regis's Reflect™ polysaccharide chiral phases and competes in the same chiral HPLC/SFC column market serving pharma separation scientists.

TypeDirect peer
Description

Phenomenex (part of Danaher) is a major manufacturer of HPLC and SFC columns including Lux chiral phases. Competes directly with Regis's chiral and reversed-phase column portfolio across pharma and life sciences end markets.

TypeDirect peer
Description

Hovione is a privately-held CDMO specializing in small-molecule APIs, including HPAPI capabilities and particle engineering. Comparable to Regis in CDMO service scope, customer type, and HPAPI specialization.

TypeDirect peer
Description

Cambrex is a leading small-molecule API CDMO offering services from preclinical through commercial manufacturing. Most direct comparable to Regis's CDMO business in scale, services, and customer base.

TypeDirect peer
Description

Siegfried is a Swiss-listed CDMO focused on small-molecule APIs from process development through commercial manufacturing. Comparable to Regis's CDMO business in target customers, service scope, and regulatory positioning.

TypeDirect peer
Description

ES Industries manufactures specialty HPLC columns including chiral phases. Similar size and specialty focus to Regis, competing in the same niche pharma and life sciences chromatography market.

TypeDirect peer
Description

Manufacturer of HALO core-shell particle columns used in HPLC and SFC. Directly comparable to Regis's WHELK-O® 1 Core core-shell columns and competes in the high-throughput chromatography segment for pharma.

TypeDirect peer
Description

YMC is a Japanese manufacturer of HPLC and SFC columns including CHIRAL ART polysaccharide chiral columns. Directly comparable to Regis in chiral and reversed-phase chromatography for pharmaceutical customers globally.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Regis Technologies

Chromatography Products and Pharmaceutical CDMOregistech.com

Regis Technologies is a US-based, cGMP-certified pharmaceutical services company operating two businesses: a proprietary chromatography column and reagent product line sold in 80+ countries, and a custom small-molecule API CDMO including HPAPI manufacturing from preclinical to commercial stages. Acquired by Spain's ESTEVE in July 2025.

What Regis Technologies does

Regis Technologies is a US-based pharmaceutical services and specialty chemistry company founded in 1956 by Dr. Louis Glunz III and headquartered at 8210 Austin Avenue, Morton Grove, Illinois. The company operates a dual-business model: a chromatography products franchise and a Custom API CDMO services franchise, both anchored at a single cGMP-certified, FDA-inspected facility.

The chromatography business manufactures and distributes high-performance packed columns for analytical and preparative separations, including chiral HPLC and SFC columns (WHELK-O® 1, recognized as USP L102; Reflect™ polysaccharide phases; AZYP chiral phases; CrownSil™ crown ether phases), achiral SFC columns (Celeris™ family), reversed-phase HPLC columns (Evoke™ C18), and immobilized artificial membrane (IAM) columns for biomimetic drug-permeability screening. Adjacent specialty and imaging reagents include ultrapure ion pairing reagents, derivatizing reagents, and bioluminescent substrates (Coelenterazine, D-Luciferin, 4-Chloro-1-Naphthol). A free in-house chiral screening service tests customer compounds across 13 stationary phases with results typically returned within 3 business days.

The CDMO division provides contract development and manufacturing services for small-molecule active pharmaceutical ingredients from preclinical through commercial stages, including analytical development, process chemistry, cGMP scale-up, clinical trial material, commercial API, and high-potency API (HPAPI) manufacturing. Customers are primarily pharmaceutical and biotechnology companies, separation scientists, and drug discovery organizations. Go-to-market combines direct enterprise sales with an authorized distributor network covering more than 80 countries, including named US distributors Chrom Tech, Fisher Scientific, Peeke Scientific, and ColumnTek. On July 30, 2025, Regis Technologies was acquired by ESTEVE (Esteve Química), a Spain-headquartered global pharmaceutical company founded in 1929, bringing approximately 70 skilled professionals into ESTEVE's US operations and positioning Regis as the US foothold of a broader CDMO platform.

Regis Technologies firmographics

Firmographics
Name
Regis Technologies
Legal name
Regis Technologies, Inc.
Website
https://registech.com
Company type
Private
Founded year
1956
Operating status
Operating
Headcount range
51–100 employees
Short description
Regis Technologies is a US-based, cGMP-certified pharmaceutical services company operating two businesses: a proprietary chromatography column and reagent product line sold in 80+ countries, and a custom small-molecule API CDMO including HPAPI manufacturing from preclinical to commercial stages. Acquired by Spain's ESTEVE in July 2025.
Ownership category
akta.pro rank

Regis Technologies industry classification

Industry
Product category
Chromatography Products and Pharmaceutical CDMO
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Chromatography columns
  • Chiral separation products
  • Pharmaceutical CDMO services
  • API contract manufacturing
  • Specialty reagents

Where Regis Technologies is headquartered

Location

Headquarters

HQ city
Morton Grove
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Regis Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Chromatography Products: Sale of chromatography columns (chiral, achiral, reversed-phase, IAM), specialty reagents (ion pairing, derivatizing, imaging), and chiral screening services. Products sold directly and through distributors.
  2. Custom API CDMO Services: Contract development and manufacturing services for active pharmaceutical ingredients from preclinical through commercial stages. Services include analytical development, process chemistry, cGMP manufacturing, quality assurance, and regulatory support.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard product pricing for chromatography columns and reagents

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Regis Technologies product offering

Product offering

Core offering

Regis Technologies manufactures and sells high-performance chromatography columns (chiral HPLC/SFC, achiral SFC, reversed-phase HPLC, IAM) and specialty/imaging reagents, and provides contract development and manufacturing (CDMO) services for small-molecule active pharmaceutical ingredients from preclinical through commercial stages, including high-potency APIs (HPAPIs). The chromatography business supplies separation scientists globally through direct sales and authorized distributors in 80+ countries, while the CDMO division serves pharmaceutical and biotechnology customers from its Morton Grove, IL facility.

Product overview

Regis Technologies operates as a dual-business company offering both chromatography products and CDMO services. The chromatography portfolio consists of specialized columns (chiral, achiral SFC, reversed-phase, IAM) and specialty/imaging reagents, with flagship products including Whelk-O® 1 chiral columns, Reflect™ Polysaccharide phases, and Celeris™ achiral SFC columns. The CDMO division provides contract manufacturing and development services for small-molecule APIs from preclinical through commercial stages, including HPAPI manufacturing. The company was acquired by ESTEVE in July 2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • Whelk-O® 1 Chiral Columns Pirkle-type chiral stationary phase columns for separating enantiomers from compound families including amides, epoxides, esters, ureas, carbamates, ethers, aziridines, phosphonates, aldehydes, ketones, carboxylic acids, and alcohols. Recognized as USP L102 and available in R,R and S,S configurations for peak elution order inversion. Used by analytical and preparative separation scientists in pharmaceutical and chemical industries.
  • Reflect™ Polysaccharide Chiral Phases High-performance polysaccharide-based chiral columns available in both coated and immobilized versions, including C-Amylose A, I-Cellulose B, and I-Cellulose C phases. Provide excellent peak shape, improved resolution, and high loading capacity for preparative applications. Sold to separation scientists for analytical and preparative chiral separations.
  • AZYP Chiral Phases Novel chiral stationary phases featuring beta-cyclodextrin, hydroxylpropyl, HILIC, alkyl derivatized cyclofructan, derivatized maltodextrin, macrocyclic glycopeptide, quinine-based, teicoplanin aglycone, teicoplanin, and vancomycin chemistries bonded to 2.7 μm superficially porous particles. Used by separation scientists for difficult chiral separations.
  • CrownSil™ Crown Ether Chiral Phases Crown ether-based chiral columns for separating chiral compounds containing primary amines and amino acids and their derivatives, including amino alcohols and secondary amines. Sold to separation scientists requiring selective amine separations.
  • Celeris™ Achiral SFC Columns Family of achiral stationary phases for supercritical fluid chromatography, including Ethyl Pyridine (2EP, 4EP), Arginine, Amino, PEI, Silica, and Diol phases. Deliver high capacity, broad selectivity, excellent peak shapes, and reproducibility over long column lifetimes. Sold to analytical and preparative separation scientists.
  • Evoke™ C18 Reversed-Phase Columns High-performance, scalable reversed-phase HPLC columns for resolving complex samples in pharmaceutical, food, environmental, forensics, and clinical applications. Sold to analytical laboratories across multiple industries.
  • IAM (Immobilized Artificial Membrane) Chromatography Columns Phosphatidylcholine-based columns that mimic biological cell membrane surfaces for high-throughput prediction of drug membrane permeability, correlating with Caco-2 and intestinal tissue assays. Sold to drug discovery and lead optimization teams for ADME screening.
  • Ion Pairing Reagents Ultrapure ion pairing reagents for improving separation of charged analytes in HPLC, available for both anions and cations. Sold to analytical laboratories performing charged-analyte separations.
  • Derivatizing Reagents High-purity GC derivatization reagents including acylation, alkylation, silylation, and chiral derivatization reagents for modifying analyte functional groups to enable chromatographic separation and detection. Sold to analytical laboratories.
  • Coelenterazine High-purity bioluminescent reagent for reporter gene assays, ELISA, HTS assays, BRET, and chemiluminescent detection of superoxides. Manufactured in FDA-inspected, GMP-certified facility. Sold to life sciences researchers.
  • D-Luciferin High-purity bioluminescent substrate for in vivo and in vitro research including reporter gene assays, whole animal imaging, luciferase assays, and ATP assays. Sold to life sciences researchers.
  • 4-Chloro-1-Naphthol Biochemical reagent with 99% purity for colorimetric detection of proteins. Sold to life sciences and analytical laboratories.
  • Free Chiral Screening Service Complimentary chiral separation screening service that tests customer compounds across 13 chiral stationary phases under HPLC or SFC conditions to identify optimal columns and methods. Results typically returned within 3 business days. Offered to separation scientists evaluating column purchases.
  • Custom API CDMO Services Contract development and manufacturing services for small-molecule active pharmaceutical ingredients from preclinical through commercial stages, including analytical development, process chemistry, cGMP manufacturing, clinical trial material, commercial API, regulatory and CMC support. Delivered from an FDA-inspected, cGMP-certified facility to pharmaceutical and biotechnology companies.
  • HPAPI Manufacturing High-potency active pharmaceutical ingredient manufacturing capabilities within cGMP facilities for compounds requiring specialized handling and containment. Delivered to pharmaceutical and biotechnology companies as part of Regis's CDMO offerings.

Quantifiable outcome

  • Improved throughput by greater than 3X with core-shell technology
  • +2 more outcomes

Companies that use Regis Technologies

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Regis Technologies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Regis Technologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ESTEVE (Esteve Química)coreStrategic or Co-development Partner · 30 July 2025ESTEVE CDMO acquired Regis Technologies in July 2025, enabling ESTEVE to expand its contract development and manufacturing services for small-molecule APIs into the US market. The acquisition provides ESTEVE with physical US presence and Regis's cGMP manufacturing capabilities and chromatography product portfolio.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Regis Technologies competitors and assessment

Company assessment

Broad incumbents

  • MilliporeSigma (Merck KGaA Life Science): MilliporeSigma is the dominant broad-line chromatography and lab supplies vendor with a comprehensive chiral and reversed-phase column portfolio. Competes with Regis across all chromatography segments but as part of a much larger lab products portfolio.

Direct peers

  • Chiral Technologies (Daicel subsidiary): Chiral Technologies, the Daicel subsidiary focused exclusively on chiral chromatography, is the most direct competitor to Regis's chiral stationary phase business. Overlaps heavily with Regis's Whelk-O® 1 and Reflect™ product lines.
  • Daicel Corporation (Chiral Technologies): Daicel, through its Chiral Technologies subsidiary, is the global market leader in polysaccharide-based chiral stationary phases (Chiralcel, Chiralpak). Direct competitor to Regis's Reflect™ polysaccharide chiral phases and competes in the same chiral HPLC/SFC column market serving pharma separation scientists.
  • Phenomenex: Phenomenex (part of Danaher) is a major manufacturer of HPLC and SFC columns including Lux chiral phases. Competes directly with Regis's chiral and reversed-phase column portfolio across pharma and life sciences end markets.
  • Hovione: Hovione is a privately-held CDMO specializing in small-molecule APIs, including HPAPI capabilities and particle engineering. Comparable to Regis in CDMO service scope, customer type, and HPAPI specialization.
  • Cambrex: Cambrex is a leading small-molecule API CDMO offering services from preclinical through commercial manufacturing. Most direct comparable to Regis's CDMO business in scale, services, and customer base.
  • Siegfried Holding AG: Siegfried is a Swiss-listed CDMO focused on small-molecule APIs from process development through commercial manufacturing. Comparable to Regis's CDMO business in target customers, service scope, and regulatory positioning.
  • ES Industries: ES Industries manufactures specialty HPLC columns including chiral phases. Similar size and specialty focus to Regis, competing in the same niche pharma and life sciences chromatography market.
  • Advanced Materials Technology: Manufacturer of HALO core-shell particle columns used in HPLC and SFC. Directly comparable to Regis's WHELK-O® 1 Core core-shell columns and competes in the high-throughput chromatography segment for pharma.
  • YMC Co., Ltd. YMC is a Japanese manufacturer of HPLC and SFC columns including CHIRAL ART polysaccharide chiral columns. Directly comparable to Regis in chiral and reversed-phase chromatography for pharmaceutical customers globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Regis Technologies social profiles

Digital presence

Regis Technologies compliance and trust

Trust signal

Compliance2 records

Regis Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Regis Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Regis Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Regis Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regis Technologies

What does Regis Technologies do?

Regis Technologies manufactures and sells high-performance chromatography columns (chiral HPLC/SFC, achiral SFC, reversed-phase HPLC, IAM) and specialty/imaging reagents, and provides contract development and manufacturing (CDMO) services for small-molecule active pharmaceutical ingredients from preclinical through commercial stages, including high-potency APIs (HPAPIs). The chromatography business supplies separation scientists globally through direct sales and authorized distributors in 80+ countries, while the CDMO division serves pharmaceutical and biotechnology customers from its Morton Grove, IL facility.

Is Regis Technologies a public or private company?

Regis Technologies is a private company. It is classified as corporate owned and is currently operating.

When was Regis Technologies founded?

Regis Technologies was founded in 1956. It employs 51 to 100 people.

Where is Regis Technologies based?

Regis Technologies is headquartered in Morton Grove, United States, in the North America region.

How does Regis Technologies make money?

Two revenue lines are on record. Chromatography Products are the primary driver. The others are custom API CDMO Services.

Who are Regis Technologies's main competitors?

MilliporeSigma (Merck KGaA Life Science) is listed as a broad incumbent. Direct peers are Chiral Technologies (Daicel subsidiary), Daicel Corporation (Chiral Technologies), Phenomenex, Hovione, Cambrex, Siegfried Holding AG, ES Industries, Advanced Materials Technology and YMC Co., Ltd..

Does Regis Technologies have an API?

No public API is recorded for Regis Technologies.

What industry is Regis Technologies in?

Regis Technologies's product category is Chromatography Products and Pharmaceutical CDMO. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceESTEVE’S EXPANSION AND GROWTH IN EU AND USA ACCELERATES ITS TRANSFORMATION INTO A GLOBAL HEALTHCARE COMPANYESTEVE reported 2025 net revenue of €828 million, up 14% year-over-year, and EBITDA of €151 million, up 19%. The company added eight new products and a US CDMO asset, and expects to reach €1 billion in net revenue in 2027.EIN PresswireU.S. CMO/CDMO Market to Reach US$149.4 Bn by 2032 at 8.7% CAGR | Persistence Market ResearchThe U.S. CMO/CDMO market is projected to grow from US$83.1 billion in 2025 to US$149.4 billion by 2032, an 8.7% CAGR. API manufacturing leads service types, and oncology is the dominant therapeutic area, with outsourcing driving demand.openPR.comLeading Companies Reinforce Their Presence in the HP (High Potency) APIs MarketThe HP (High Potency) APIs market is projected to reach $42.56 billion by 2030, growing at a compound annual growth rate of 9.4%, driven by increasing use in oncology and hormonal treatments and expanding contract manufacturing. In July 2025, Spain-based ESTEVE Pharmaceuticals, S.A. completed the acquisition of U.S.-based Regis Technologies Inc., a contract development and manufacturing organization specializing in HP APIs, aiming to bolster its U.S. footprint and manufacturing capabilities. Additionally, UK-based CatSci Ltd. partnered with AGC Pharma Chemicals Europe S.L.U. in March 2023 to offer expanded manufacturing processes including fluorination and bromination.InvestorshangoutESTEVE CDMO Strengthens Presence with Regis Technologies BuyoutESTEVE CDMO acquired Regis Technologies, a US-based API CDMO founded in 1956, to expand its contract development and manufacturing services. The deal adds about 70 skilled professionals to ESTEVE's US team and strengthens its position in small-molecule API development from pre-clinical to commercial manufacturing.PR NewswireESTEVE Acquires Regis Technologies, expanding U.S. presence and capabilitiesESTEVE acquired Regis Technologies, a US-based CDMO, to expand its contract development and manufacturing services for small-molecule APIs from pre-clinical to commercial manufacturing. The deal adds about 70 skilled people and a physical presence in the US, with Regis offering process R&D, cGMP API manufacturing, and chromatography products.PR NewswireESTEVE Acquires Regis Technologies, expanding U.S. presence and capabilitiesESTEVE has acquired Regis Technologies, a U.S.-based Contract Development and Manufacturing Organization headquartered in Chicago, marking ESTEVE's first physical presence in the United States. The acquisition expands ESTEVE's contract development and manufacturing solutions for innovative small-molecule active pharmaceutical ingredients across the entire drug development lifecycle from pre-clinical to commercial manufacturing. Regis Technologies brings approximately 70 skilled employees and over 65 years of API CDMO experience to ESTEVE's global operations spanning facilities in Spain, Mexico, China, and now the United States.PR NewswireESTEVE adquiere Regis Technologies, ampliando su presencia y capacidades en EE.UU.ESTEVE has acquired Regis Technologies, a U.S.-based contract development and manufacturing organization (CDMO) headquartered in Chicago, Illinois, expanding its footprint in the United States. The acquisition enables ESTEVE CDMO (operating as Esteve Química) to offer end-to-end services for the development and manufacturing of small-molecule active pharmaceutical ingredients, from preclinical through commercial production phases. Regis Technologies brings over 65 years of API CDMO experience and FDA-inspected cGMP manufacturing capabilities to ESTEVE's existing network of production plants in Spain, Mexico, and China.PR NewswireESTEVE erwirbt Regis Technologies, , und erweitert damit seine Präsenz und sein Angebot in den USAESTEVE, a Barcelona-based global pharmaceutical company, has acquired Regis Technologies, a US-based Contract Development and Manufacturing Organization (CDMO) headquartered in Chicago, for an undisclosed amount. The acquisition grants ESTEVE CDMO (operating as Esteve Química) its first physical presence in the United States, expanding its contract development and manufacturing services for small molecule pharmaceutical APIs from preclinical through commercial production. Regis Technologies, founded in 1956, brings approximately 70 qualified employees and capabilities including process research, analytics, stability studies, cGMP API manufacturing, and CMC support.PR NewswireESTEVE acquiert Regis Technologies et étend sa présence ainsi que ses capacités aux États-UnisESTEVE, a Barcelona-based international pharmaceutical company, has acquired Regis Technologies, a US-based contract development and manufacturing organization (CDMO) headquartered in Chicago. The acquisition enables ESTEVE CDMO (operating as Esteve Química) to establish its first physical presence in the United States and expand its contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) across the full drug development cycle from preclinical to commercial manufacturing. Regis Technologies, founded in 1956, brings approximately 70 qualified employees, FDA-inspected facilities, and capabilities including process R&D, GMP API manufacturing, analytics, stability testing, and chromatography products.Business & FinancialESTEVE CDMO Acquires Regis Technologies, Expanding U.S. Presence And CapabilitiesESTEVE CDMO (Esteve Química) has acquired U.S.-based CDMO Regis Technologies, headquartered in Chicago, Illinois. The acquisition provides ESTEVE with its first physical presence in the United States, adding around 70 employees and extending its API manufacturing capabilities from pre-clinical development through commercial production. Regis Technologies, founded in 1956 and privately owned, will now operate under ESTEVE's CDMO division, combining its chromatography products and cGMP manufacturing expertise with ESTEVE's global network.